Galapagos

News

Galapagos abandons cell therapy, putting 365 jobs at risk

Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it seeks 'transformative' deals for its drugs unit.

News

Galapagos drops plan to split after 'market developments'

Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.

News

Galapagos' chief executive Paul Stoffels

Galapagos unveils plan to split, hiving off its drugs unit

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

News

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita

News

Galapagos' new CEO Paul Stoffels wields axe in bid to go 'fo...

When long-serving Johnson & Johnson R&D chief Paul Stoffels cut short his retirement to

News

Paul Stoffels swiftly resurfaces as Galapagos' next CEO

Paul Stoffels' retirement at the end of last year after nine years as head of R&D at Johnson & Johnson was short lived – he's just been named chef executive of Galapagos.

Galapagos abandons cell therapy, putting 365 jobs at risk

Galapagos drops plan to split after 'market developments'

Galapagos unveils plan to split, hiving off its drugs unit

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos' new CEO Paul Stoffels wields axe in bid to go 'fo...

Paul Stoffels swiftly resurfaces as Galapagos' next CEO

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

Galapagos

Editor's Picks